I-Mab Biopharma’s Gastric Cancer Breakthrough: 71% Response Rate Sparks Hope
I-Mab Biopharma, a clinical-stage biopharmaceutical company, has made significant strides in cancer treatment with promising results from its gastric cancer medication and Phase 1b study, solidifying its position as a beacon of hope in the fight aga…
3 minutes to read